Skip to main content
BioCentury on BioBusiness
Feature Story

Califf's agenda

Califf's busy agenda as FDA commissioner would include clinical trial reform

By Steve Usdin, Washington Editor

Senate Democrats and Republicans last week drove a stake through allegations that Robert Califf's past interactions with pharmaceutical companies render him unsuitable to serve as commissioner of FDA. Strong bipartisan support from the Health, Education, Labor and Pensions Committee shifts the conversation from whether Califf will be confirmed to what he can accomplish in the fleeting time before the curtain falls on the Obama administration.

Theoretically, the next president could retain Califf, but realistically he can't count on spending much more than a year in the top job.

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial